BioMedNewsBreaks

ThursdaySep 10, 2020 12:09 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 – Probenecid Combination

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, recently announced positive new data from the company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. According to the update, results of the new study complement previous preclinical data demonstrating the combination's potential to substantially increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, a potent and selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing NMDA receptor signaling. "These new positive results amplify our message that AV-101, when administered in…

Continue Reading

WednesdaySep 09, 2020 11:53 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene…

Continue Reading

TuesdaySep 08, 2020 2:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of invaluable combined experience and life-science, business-development, marketing and financial expertise. An article discussing this quotes POAI CEO Dr. Carl Schwartz, who stated, “These appointments signify our absolute commitment to aligning our board’s expertise with the company’s strategic vision of developing and commercializing an offering that…

Continue Reading

ThursdaySep 03, 2020 11:12 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Progress Report on Critical Steps for Manufacturing of Leading Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has provided updated information on the manufacturing of its lead drug candidate, Berubicin. The company announced it has reached key milestones in the manufacturing process as it has followed a dual-track, drug-product manufacturing strategy; CNS is working with both U.S.-based Pharmaceutics International Inc. (“Pii”) and Italy-based BSP Pharmaceuticals S.p.A. (“BSP”) in producing Berubicin. “As we prepare to initiate our upcoming Berubicin clinical trials, our execution both on the clinical and manufacturing fronts remain paramount to our…

Continue Reading

WednesdaySep 02, 2020 2:25 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Discusses Transformation to B2B2C Digital Therapeutics

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, has recently achieved a series of successes and anticipates even more in the coming weeks. Among drivers of DRIO’s path toward leading cutting-edge solutions is the global pandemic, which has unveiled dynamics of the company’s business model that provide distinction in an era in need of next-generation health care. A recent article discussing this includes commentary from DarioHealth’s CEO Erez Raphael, who stated, “The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (‘B2B2C’) digital therapeutics leader. We advanced late-stage discussions with health plans and…

Continue Reading

WednesdaySep 02, 2020 12:39 pm

BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) to Evaluate Psilocybin in Methamphetamine Use Disorder Treatment Clinical Trial

Revive Therapeutics (CSE: RVV) OTC: RVVTF), a specialty life-sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has finalized a clinical trial agreement with the Board of Regents of the University of Wisconsin System (“UWS”). The agreement calls for Revive Therapeutics to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The agreement calls for Revive Therapeutics to have an option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may obtain in any…

Continue Reading

WednesdaySep 02, 2020 11:20 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints New VP to Oversee Regulatory Affairs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon brings invaluable expertise in the areas of clinical development, regulatory affairs and commercialization of products. He is currently chief scientific officer and medical director at Capital City Technical Consulting, where he has directed clinical trial development and operations management for clients in both the biotech…

Continue Reading

WednesdaySep 02, 2020 10:39 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that company executives will be presenting at LD Micro’s elite LD 500 Virtual Investor Conference. The presentation is scheduled for Wednesday, Sept. 2, 2020, at 3:40 p.m. ET. An archived copy of the webcast will be available for 90 days following the live presentation. To watch the live webcast of the presentation, visit http://ibn.fm/QS1EB To view the full press release, visit http://ibn.fm/Pcn1n About Predictive Oncology Inc. Predictive Oncology operates through three segments (domestic, international and other), which contain four…

Continue Reading

FridayAug 28, 2020 12:58 pm

BioMedNewsBreaks – Exciting Opportunity for Clinical Quality Professionals Coming in Fall 2020

Clinical Document World promises to be the year’s learning and networking event for life science professionals. The virtual event, produced by Lincoln Health Network and slated to take place from Sept. 15-18, 2020, is designed to enhance attendees’ clinical trial document process in order to have a complete Trial Master File (“TMF”) as well as enable their businesses to improve clinical quality, implement new technology and be inspection ready. Clinical Document World offers over 45 educational sessions that cover all aspects of clinical document management, including regulatory guidance, compliance, quality, and technology. Ideal attendees are life science professionals from pharmaceutical,…

Continue Reading

ThursdayAug 27, 2020 3:01 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (PCSA) Enters Exclusive Agreement to Expand Pipeline, Oncology Involvement

Processa Pharmaceuticals (OTCQB: PCSA), today announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (“PCS6422”) globally. According to the update, PCS6422 is an oral drug designed to be administered with fluoropyrimidine cancer drugs (i.e., “capecitabine,” “5-FU”) in order to decrease their breakdown to inactive metabolites or metabolites known to cause unwanted side effects and interfere with the anticancer activity. “Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact…

Continue Reading